Wegovy Goes Global: How One Drug Is Reshaping Healthcare Economics and Ethics Worldwide

# Podcast Episode Description **Wegovy's Global Takeover: How One Drug Is Reshaping Economies, Healthcare, and Ethics Worldwide** Wegovy has evolved from a weight loss medication into a force reshaping global health policy, national economies, and pharmaceutical markets. In this episode, we trace semaglutide's expanding footprint across the world—from China's regulatory review of oral Wegovy tablets to Denmark's economic growth forecast upgrade tied directly to the drug's success. **In this episode, we cover:** - **China's regulatory breakthrough**: Novo Nordisk's oral Wegovy application now under formal review by China's National Medical Products Administration - **Economic impact**: How Wegovy sales boosted Denmark's 2026 GDP growth forecast to 3.7% - **Wall Street's mixed signals**: Novo Nordisk stock pressure despite regulatory wins, amid fierce competition from Eli Lilly's Mounjaro - **Medicare's Bridge Program**: How U.S. seniors are accessing Wegovy for $50/month—and who gets left out - **India's generic drug paradox**: Why cheap semaglutide alternatives aren't selling as projected - **Telehealth safety concerns**: An Australian case raising red flags about GLP-1 prescriptions without proper psychological screening - **Beyond weight loss**: New research exploring semaglutide for alcohol use disorder and MASH (fatty liver disease) This episode connects the dots between pharmaceutical innovation, healthcare equity, market speculation, and the human stories behind the headlines. Whether you're tracking Novo Nordisk's stock, curious about GLP-1 drugs' expanding uses, or interested in how weight loss medications are reshaping global health policy, this de Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai